Biodegradable Intranasal Fluticasone Matrix for Long-Term Release

The patent applies preliminary action by pre-loading the intranasal device with fluticasone propionate during manufacturing. The device is prepared in advance with the active ingredient embedded in the polymer matrix, so that when inserted into the nasal cavity, the drug is already positioned for sustained release without requiring frequent user application. This resolves the contradiction by maintaining ease of administration (simple insertion) while achieving extended duration of action (up to 12 months).

The patent implements continuity of useful action through the biodegradable polymer matrix that continuously releases fluticasone propionate over extended periods (6-12 months). The polymer structure maintains stable drug release through controlled degradation, ensuring uninterrupted therapeutic action. This eliminates the need for frequent reapplication while maintaining effective drug delivery, resolving the contradiction between duration of action and ease of administration.

The patent applies parameter changes by selecting and optimizing specific polymer parameters (molecular weight, composition, degradation rate) to achieve sustained release over 6-12 months. By carefully controlling polymer characteristics such as using poly(glycolic acid)-poly(lactic acid) copolymers with specific ratios and molecular weights, the device achieves extended duration of action without requiring complex mechanical structures. This resolves the contradiction by extending duration through material parameter optimization rather than increasing device complexity.

The patent utilizes composite materials by combining fluticasone propionate with biodegradable polymer matrices (poly(glycolic acid), poly(lactic acid), and their copolymers). This composite structure enables sustained release through controlled polymer degradation while maintaining relatively simple device geometry. The composite material approach achieves extended duration of action (6-12 months) without significantly increasing device complexity, as the sustained release function is embedded in the material composition rather than requiring complex mechanical mechanisms.

The patent applies parameter changes by optimizing polymer molecular weight, composition ratios, and crystallinity parameters to achieve precise control over degradation time while maintaining mechanical integrity for 6-12 months. By adjusting parameters such as polymer molecular weight and copolymer composition, the degradation rate can be precisely tuned to match the required duration of action. This resolves the contradiction by achieving stable mechanical properties through parameter optimization rather than complex structural design.

The patent uses composite materials with specific polymer combinations (poly(glycolic acid)-poly(lactic acid) copolymers) that provide balanced mechanical stability and controlled degradation. The composite material structure allows simultaneous achievement of long-term mechanical integrity and predictable degradation over 6-12 months. The material composition itself provides the degradation control mechanism, eliminating the need for complex external control systems. This resolves the contradiction by embedding both stability and controlled degradation within the material composition.